The effect of VH peptide vaccination on the antidextran humoral response
Vaccination group and mouse no. . | Antidextran Ab, μg/mL . |
|---|---|
| Control | |
| 1-1 | 264 |
| 1-2 | 342 |
| 1-3 | 263 |
| 1-4 | 125 |
| 1-5 | 201 |
| Mean | 239 |
| Dcs alone | |
| 2-1 | 221 |
| 2-2 | 239 |
| 2-3 | 272 |
| 2-4 | 351 |
| 2-5 | 240 |
| Mean | 265 |
| VH peptide vaccine* | |
| 3-1 | 263 |
| 3-2 | 219 |
| 3-3 | 365 |
| 3-4 | 160 |
| 3-5 | 163 |
| Mean | 234 |
Vaccination group and mouse no. . | Antidextran Ab, μg/mL . |
|---|---|
| Control | |
| 1-1 | 264 |
| 1-2 | 342 |
| 1-3 | 263 |
| 1-4 | 125 |
| 1-5 | 201 |
| Mean | 239 |
| Dcs alone | |
| 2-1 | 221 |
| 2-2 | 239 |
| 2-3 | 272 |
| 2-4 | 351 |
| 2-5 | 240 |
| Mean | 265 |
| VH peptide vaccine* | |
| 3-1 | 263 |
| 3-2 | 219 |
| 3-3 | 365 |
| 3-4 | 160 |
| 3-5 | 163 |
| Mean | 234 |
Ab indicates antibody.
DCs pulsed with the 3 germ line MHC class I peptides (A9T[Fr3], K9I[Fr2/CDR2], S9L[Fr3]) and 3 germ line MHC class II VH peptides (G16K[Leader/Fr1], F17L[Fr1/CDR1/Fr2], A15V[Fr3]) used in the tumor protection studies shown in Figure 4. P > .5 for all comparisons. These data are representative of 2 independent experiments.